Company profile
SAVARA INC
NASDAQ:SVRABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MOLGRAMOSTIM | phase3 | — | 5 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03181932 | phase3 | completed | 2017-09-20 | 2020-07-28 | Savara Inc. | AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis |
| NCT04544293 | phase3 | active_not_recruiting | 2021-05-19 | 2023-11-30 | Savara Inc. | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) |
| NCT01746095 | phase2 | completed | 2013-03-01 | 2014-11-01 | Savara Inc. | Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients |
| NCT02702180 | phase2 | completed | 2016-03-21 | 2019-04-19 | Savara Inc. | Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis |
| NCT02468908 | phase1 | completed | 2015-05-01 | 2015-10-01 | Savara Inc. | Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects |
FDA applications (0)
No records yet.